Premium
Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia
Author(s) -
BerthelotRicher Maxime,
Boilard Brigitte,
Morin Annie,
Bolduc Brigitte,
Beauregard Patrice,
Kotb Rami
Publication year - 2012
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2011.03382.x
Subject(s) - romiplostim , medicine , refractory (planetary science) , myeloid leukemia , platelet transfusion , hematology , acute leukemia , complication , platelet , blood transfusion , leukemia , intensive care medicine , thrombopoietin , haematopoiesis , stem cell , genetics , physics , astrobiology , biology
BACKGROUND: Refractoriness to platelet (PLT) transfusion is a feared, life‐threatening complication in hematology‐oncology patients. Despite increased PLT requirement and treatment costs, the clinical management is difficult and these patients had less favorable outcomes. CASE REPORT: We report on the efficacy of the thrombopoietic agent romiplostim in a patient with acute myeloid leukemia with chemotherapy‐induced transfusion‐refractory thrombocytopenia. CONCLUSION: Romiplostim could be very helpfull in the management of AML patients with transfusion refractory thrombocytopenia.